tbuckley/cabot-search huggingface dataset:
Increased Transferrin Concentration Ameliorates Anemia in Beta-Thalassemic Mice Through Changes in Iron Uptake and TfR1 Trafficking
Authors: Huihui Li, Lionel Blanc, Tenzin Choesang, Maya Shvartsman, Leni vonBonsdorff, Zvi Ioav Cabantchik, Yelena Ginzburg
Journal: Blood (2011)
At-Home Management of Aplastic Phase Following High-Dose Melphalan and Autologous Haematopoietic Stem Cell Transplantation for Multiple Myeloma Patients: A Pilot Study
Authors: Massimo Martino, Grazia Pellicano’, Tiziana Moscato, Elisabetta Massara, Roberta Fedele, Giuseppe Console, Letteria Russo, Giuseppe Messina, Rosalba Di Filippo Scali, Giuseppe Irrera
Journal: Blood (2011)
Abstract 2058: RHOA inactivation enhances Wnt signaling and promotes colorectal cancer
Authors: Paulo Rodrigues, Irati Macaya, Sarah Bazzocco, Elena Andretta, Rocco Mazzolini, Higinio Dopeso, Silvia Mateo-Lozano, Josipa Bilic, Fernando Cartón-García, Rocio Nieto, Lucia Suárez-López, Elsa Afonso, Stefania Landolfi, Javier Hernandez-Losa, Kazuto Kobayashi, Santiago Ramón y Cajal, Josep Tabernero, Niall C. Tebbutt, John M. Mariadason, Simo Schwartz Jr, Diego Arango
Journal: Cancer Research (2015)

Abstract Activation of the small GTPase RHOA has strong oncogenic effects in many tumor types, although its role in colorectal cancer remains unclear. We show that RHOA inactivation contributes to colorectal cancer progression/metastasis, largely through the activation of Wnt/β-catenin signaling. RhoA inactivation in the murine intestine accelerates the tumorigenic process and in human colon cancer cells leads to the redistribution of β-catenin from the membrane to the nucleus and enhanced Wnt/β-catenin signaling, resulting in increased proliferation, invasion and de-differentiation. In mice, RHOA inactivation contributes to colon cancer metastasis and reduced RHOA levels were observed at metastatic sites compared to primary human colon tumors. Therefore, we have identified a new mechanism of activation of Wnt/β-catenin signaling and characterized the role of RHOA as a novel gene with tumor suppressor activity in colorectal cancer. These results constitute a shift from the current paradigm and demonstrate that RHO GTPases can suppress tumor progression and metastasis. Citation Format: Paulo Rodrigues, Irati Macaya, Sarah Bazzocco, Elena Andretta, Rocco Mazzolini, Higinio Dopeso, Silvia Mateo-Lozano, Josipa Bilic, Fernando Cartón-García, Rocio Nieto, Lucia Suárez-López, Elsa Afonso, Stefania Landolfi, Javier Hernandez-Losa, Kazuto Kobayashi, Santiago Ramón y Cajal, Josep Tabernero, Niall C. Tebbutt, John M. Mariadason, Simo Schwartz Jr, Diego Arango. RHOA inactivation enhances Wnt signaling and promotes colorectal cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2058. doi:10.1158/1538-7445.AM2015-2058
Targeted Next Generation Sequencing of the Five Hemochromatosis Genes in Italian Patients with Iron Overload and Non-Diagnostic First Level Genetic Test: A Pilot Study
Authors: Sadaf Badar, Fabiana Busti, Giampiero Zamperin, Alberto Ferrarini, Paolo Bozzini, Daniele Manna, Natascia Campostrini, Giovanna De Matteis, Massimo Delledonne, Domenico Girelli
Journal: Blood (2014)
Sequential Arsenic Trioxide, and All Trans Retinoic Acid with Daunomycin Yield Early Cytogentic and Molecular Response in Newly Diagnosed Acute Promyelocytic Leukemia – Data From a Tertiary Cancer Centre.
Authors: Hari Menon, Santosh Kumar, Manju Sengar, Pratibha Amare, Anuradha Chougule, Uma Dangi, Navin Khattry, Reena Nair
Journal: Blood (2012)
Initial Genomic Analysis of a Pure Erythroid Leukemia Developing in Association with Hydroyurea Treatment for Sickle Cell Anemia
Authors: Zhengyuan Wang, Deepika S. Darbari, J. Joseph Melenhorst, Zachariah A. McIver, Irina Maric, Lena Diaw, Young Song, Peter Johansson, Jianbin He, Zhou Weiyin, Kevin B. Jacobs, Jun Wei, A. John Barrett, Javed Khan, James G. Taylor
Journal: Blood (2012)
Benzodiazepine-423, an Inhibitor of Mitochondrial Respiration, Causes Selective Apoptosis of Activated Lymphocytes and Reverses Experimental GVHD While Preserving GVL Effects.
Authors: Erin Gatza, Shawn G. Clouthier, Pavan Reddy, Chen Liu, Anthony W. Opipari, Gary D. Glick, James L.M. Ferrara
Journal: Blood (2007)
Issues of “Cost, Capabilities, and Scope” in Characterizing Adoptees' Lack of “Genetic-Relative Family Health History” as an Avoidable Health Disparity: Response to Open Peer Commentaries on “Does Lack of ‘Genetic-Relative Family Health History’ Represent a Potentially Avoidable Health Disparity for Adoptees?”
Authors: Thomas May, James P. Evans, Kimberly A. Strong, Kaija L. Zusevics, Arthur R. Derse, Jessica Jeruzal, Alison LaPean Kirschner, Michael H. Farrell, Harold D. Grotevant
Journal: The American Journal of Bioethics (2016)
Many children receive no discharge plan after admission for severe asthma
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Children admitted to hospital with severe asthma attacks generally receive “very effective and efficient” treatment and care, but more attention must be given to asthma education and review at discharge to help prevent future attacks and readmission, says a national audit by the British Thoracic Society.

The society’s National Paediatric Asthma Audit,1 published on 29 November, reviewed data on more than 5500 children over the age of 1 admitted with severe asthma attacks to 153 UK hospitals in November 2015 and found that most aspects of discharge from hospital were less than optimal.

Some 15% of the children were readmitted to hospital by 31 …
Clinicopathological Characteristics and Clinical Course of CD8 Expressing Primary Cutaneous Peripheral T-Cell Lymphomas (CTCL) - Retrospective Case Study
Authors: Deniz Peker, Yizhou Zhang, Young Yu, Zhigang Zhao, Yafei Wang, Hongliang Yang, Frank Glass, Lynn Moscinski, Lubomir Sokol, Ling Zhang
Journal: Blood (2011)
Successful Treatment with Imatinib Mesylate Significantly Decreases Plasma Levels of Vascular Endothelial Growth Factor (VEGF) and Soluble Endoglin (sCD105) but Not Basic Fibroblast Growth Factor (bFGF) or Angiopoietin-2 (Ang-2) in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase
Authors: Lukas Smolej, Ctirad Andrys, Jaroslava Voglova, Petra Belohlavkova, Jana Rabasova, Martin Beranek, Jaroslav Maly
Journal: Blood (2008)
Descriptive Analysis and Review of Utilization of Rituximab In the Maintenance Treatment of Non-Hodgkin's Lymphoma In Five University Teaching Hospitals In Quebec, Canada.
Authors: Nathalie Letarte, France Varin, Daniel Froment, Elaine Pelletier, Benoit Bailey, Martin Turgeon, Benoit Cossette, Paul Farand, Marie-Claude Michel, Nathalie Marcotte, Louise Deschenes, Raghu Rajan, Celine Dupont
Journal: Blood (2010)
ATIM-31. ALLOGENEIC TUMOR LYSATE / AUTOLOGOUS DENDRITIC CELL VACCINES IN NEWLY DIAGNOSED GLIOBLASTOMA: CLINICAL TRIAL MC1272
Authors: Ian F. Parney, Michael P. Gustafson
Journal: Neuro-Oncology (2016)

Dendritic cell (DC) vaccines for glioblastoma multiforme (GBM) have been promising in pre-clinical studies but clinical translation has been modest due to limitations imposed by source of antigens, poor DC maturation, and tumor-mediated immunosuppression. We report preliminary findings from a clinical trial combining a DC vaccine strategy that addresses these issues with standard therapy in newly diagnosed GBM. Twenty adult patients with resected newly diagnosed GBM who had completed radiation / concurrent temozolomide were enrolled. DC’s were generated in vitro from patients’ CD14+ monocytes with an optimized technique for DC maturation. Vaccines were generated by pulsing autologous DC’s with allogeneic tumor lysate from two patient-derived allogeneic human GBM cell cultures with defined tumor antigen expression. Patients received temozolomide plus vaccine for up to 6 cycles followed by vaccine alone for up to 6 cycles. Patients enrolled were relatively enriched for poor prognostic factors (45% subtotal resection, 25% multifocal, 20% bilateral, 95% IDH wild type, 70% MGMT promotor unmethylated). Vaccine manufacture was successful (≥ 15 doses of mature, > 70% CD83+ DC’s) in all patients. Treatment has been well tolerated with only grade 1 – 2 toxicities (fever, rash, fatigue) potentially related to the vaccine. Increased circulating tumor-associated antigen-specific CD8 T-cells have been demonstrated post-vaccination with dextramer flow cytometry. Mean follow-up to date is 0.98 years (range 0.19 – 1.77 years); 16/20 patients are still alive. In the first 8 patients, median survival has not been reached with median follow-up 1.56 years. Post-vaccination tumor samples demonstrated moderate/marked inflammatory infiltrates in 5/7 biopsies. Autologous mature DC / allogeneic tumor lysate vaccines combined with temozolomide are safe, feasible, and generate tumor antigen-specific immune responses in a broad spectrum of newly diagnosed GBM patients. Initial survival data is promising, particularly in light of poor baseline prognostic factors in patients enrolled.
NON-Permissive HLA-DPB1 T CELL Epitope Disparities Correlate with Engraftment and Survival after Unrelated Stem Cell Transplantation
Authors: Roberto Crocchiolo, Elisabetta Zino, Nicoletta Sacchi, Jessica Marcon, Simona Pollichieni, Rosi Oneto, Giuseppe Bandini, Andrea Bacigalupo, Fabio Ciceri, Katharina Fleischhauer
Journal: Blood (2008)
A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids
Authors: Amin M. Alousi, Roland Bassett, Julianne Chen, Bethany J Overman, Chitra M. Hosing, Uday R. Popat, Elizabeth J. Shpall, Yago Nieto, Muzaffar H. Qazilbash, Issa F. Khouri, Partow Kebriaei, Sairah Ahmed, Nina Shah, Katayoun Rezvani, Kayo Kondo, Stefan O. Ciurea, Sharon R Hymes, Joyce L Neumann, Jeffrey J. Molldrem, Tamera R Plair, Richard E. Champlin
Journal: Blood (2015)
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer
Authors: Miles A. Miller, Ryan J. Sullivan, Douglas A. Lauffenburger
Journal: Clinical Cancer Research (2016)

Proteases known as sheddases cleave the extracellular domains of their substrates from the cell surface. The A Disintegrin and Metalloproteinases ADAM10 and ADAM17 are among the most prominent sheddases, being widely expressed in many tissues, frequently overexpressed in cancer, and promiscuously cleaving diverse substrates. It is increasingly clear that the proteolytic shedding of transmembrane receptors impacts pathophysiology and drug response. Receptor substrates of sheddases include the cytokine receptors TNFR1 and IL6R; the Notch receptors; type-I and -III TGFβ receptors; receptor tyrosine kinases (RTK) such as HER2, HER4, and VEGFR2; and, in particular, MET and TAM-family RTKs AXL and Mer (MerTK). Activation of receptor shedding by mechanical cues, hypoxia, radiation, and phosphosignaling offers insight into mechanisms of drug resistance. This particularly holds for kinase inhibitors targeting BRAF (such as vemurafenib and dabrafenib) and MEK (such as trametinib and cobimetinib), along with direct sheddase inhibitors. Receptor proteolysis can be detected in patient fluids and is especially relevant in melanoma, glioblastoma, lung cancer, and triple-negative breast cancer where RTK substrates, MAPK signaling, and ADAMs are frequently dysregulated. Translatable strategies to exploit receptor shedding include combination kinase inhibitor regimens, recombinant decoy receptors based on endogenous counterparts, and, potentially, immunotherapy. Clin Cancer Res; 23(3); 623-9. ©2016 AACR.
Cognitive remediation for negative symptoms of schizophrenia: A network meta-analysis
Authors: Matteo Cella, Antonio Preti, Clementine Edwards, Tabitha Dow, Til Wykes
Journal: Clinical Psychology Review (2016)

Cognitive remediation (CR) is a treatment targeting cognitive difficulties in people with schizophrenia. Recent research suggested that CR may also have a positive effect on negative symptoms. This meta-analysis investigates the effect of CR on negative symptoms. A systematic search was used to identify all randomized-controlled trials of CR in people with schizophrenia reporting negative symptoms outcomes. Levels of negative symptoms at baseline, post-therapy and follow-up, sample demographics and treatment length were extracted. Study methodological quality and heterogeneity were addressed. Negative symptoms standardized mean change was calculated using Hedges's g and used as the main outcome. The search identified 45 studies reporting results for 2511 participants; 15 studies reported follow-up outcomes. CR was associated with a reduction of negative symptoms (most conservative model g = − 0.30; 95% CI: − 0.36, − 0.22) at post-therapy compared with treatment as usual and this effect was larger at follow-up (g = − 0.36; 95% CI: − 0.51, − 0.21). Drop-out rate was comparable between conditions. Network meta-analysis confirmed CR was superior to TAU and TAU plus active control or adjunctive treatment. No evidence of publication bias was found. Studies with more rigorous methodology were associated with larger negative symptom reduction (g = − 0.40; 95% CI: − 0.51 to − 0.30). Although negative symptoms have not been considered a primary target for CR, this intervention can have small to moderate beneficial effects on this symptom cluster. Future research should explore in detail the active mechanisms responsible for negative symptom reduction and the relationship between cognitive and negative symptoms in schizophrenia.
Large Scale Expansion of Human Dendritic Cells with Regulatory Function from Peripheral Blood Monocytes Employing Leukapheresis and Rapamycin for Clinical Trials.
Authors: Masahiro Ogasawara, Shinsuke Asanuma, Shinsuke Noguchi, Atsushi Yasumoto, Akinori Wada, Shuuichi Ohta, Masanobu Nakata, Kiyotoshi Imai, Teiichi Hirano, Naoki Kobayashi, Yoshio Kiyama, Junji Tanaka, Masahiro Imamura, Masaharu Kasai
Journal: Blood (2007)
Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions
Authors: Yvette C. Cozier
Journal: European Respiratory Journal (2016)

Sarcoidosis is a chronic systemic disorder characterised by granulomatous inflammation targeted to an as-yet-unidentified antigen [1]. First described over 100 years ago by Caesar Boeck and others [2], sarcoidosis occurs worldwide and affects men and women of all ages and races [3–5]. The disease shows a consistent predilection for adults, with peak incidence occurring primarily before 40 years of age [3–6], although older age at onset has been widely reported [7–10]. Clinical presentation of sarcoidosis can be quite variable [11, 12], ranging from asymptomatic disease [3, 4], or acute onset with resolution [13, 14], while other patients experience chronic progressive illness affecting various organ systems and requiring systemic therapy [13–15]. Pulmonary disease affects the vast majority of diagnosed patients, but other organ systems are often affected as well [3, 4, 6]. Chronic progressive disease may require long-term treatment with corticosteroids, cytotoxics and other agents that have serious side-effects [3, 16, 17]. The lifetime risk of death is estimated to be between 1.0% and 7.6% [17, 18], with deaths attributed to respiratory, neurological or cardiovascular system involvement [19, 20]. Population-based studies reveal higher sarcoidosis morbidity and earlier mortality among males <http://ow.ly/PcWr304uAKc>
Induced Pluripotent Stem Cells From a Patient with Reticular Dysgenesis Recapitulate Defective Myelopoiesis in-Vitro: A Disease Model to Enhance Our Understanding of a Rare Disease.
Authors: Katja G. Weinacht, Kerstin Felgentreff, Alex Devine, Axel Schambach, Waleed Al-herz, Luigi Daniele Notarangelo
Journal: Blood (2012)
Obesity Is a Poor Prognostic Factor In Acute Promyelocytic Leukemia (APL).
Authors: Yoshihiro Hatta, Akira Horikoshi, Daisuke Kurita, Sumiko Kobayashi, Yujin Kobayashi, Yoshimasa Kura, Hitomi Kodaira, Yasuyuki Inoue, Katsuhiro Miura, Satomi Kiso, Hiromichi Takahashi, Hikari Ishizuka, Toshitake Tanaka, Mai Yagi, Atsuko Hojo, Yukio Hirabayashi, Yoshihito Uchino, Noriyoshi Iriyama, Umihiko Sawada, Jin Takeuchi
Journal: Blood (2010)
Intense Reversal of Bone Marrow Angiogenesis after Consolidation Therapy with Alemtuzumab in Advanced Chronic Lymphocytic Leukemia.
Authors: Stefano Molica, Marco Montillo, Domenico Ribatti, Rosanna Mirabelli, Alessandra Tedeschi, Francesca Ricci, Silvio Veronese, Angelo Vacca, Enrica Morra
Journal: Blood (2006)
Biosimilar Therapy for ERBB2 (HER2)–Positive Breast Cancer
Authors: Harold J. Burstein, Deborah Schrag
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vincristine Potentiates the Anti-Leukemia Effect of the Aurora Kinase Inhibitor VE-465 by Enhancing Apoptosis in Myeloid Leukemia Cells.
Authors: Ken Ohmine, Tadashi Nagai, Kozue Yoshida, Shin-ichiro Fujiwara, Mitsuyo Uesawa, Chihiro Sakurai, Keiya Ozawa
Journal: Blood (2009)
Clinical and Haematological Features of Genetic Mutations in MPN Patients with Diagnosis of Prefibrotic Idiopathic Myelofibrosis (MF0)
Authors: Bruno Martino, Claudia Labate, Bruna Greve, Domenica Ielo, Domenico Rotilio, Corrado Mammì, Carmelo Laganà, Francesca Ronco
Journal: Blood (2015)
Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).
Authors: Emilio Iannitto, Stefano De Cantis, Viviana Minardi, Vincenzo Callea, Giuseppina Calvaruso, Antonino Mulè, Emanuele Ammatuna, Caterina Stelitano, Claudio Tripodo, Achille Ambrosetti, Giovanni Pizzolo, Ada Florena, Vito Franco, Ada Florena
Journal: Blood (2004)
Autologous Transplantation in De Novo Non-Promyelocytic Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) with Peripheral Blood Stem Cell (PBSC) Collection Following Consolidation with High-Dose Cytarabine and Etoposide: A Single Institution Experience
Authors: Eugene Choi, Lingyi Chen, Srikanth Nagalla, Vamshi Kaveti, Regina Mullaney, Akhil Chopra, Kristine Ward, Michael Styler, David Topolsky, Pamela Crilley
Journal: Blood (2008)
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.
Authors: Matilde Y Follo, Sara Mongiorgi, Cristina Clissa, Francesca Chiarini, Stefania Paolini, Michele Baccarani, Giovanni Martinelli, Lucia Manzoli, Alberto M. Martelli, Carlo Finelli, Lucio Cocco
Journal: Blood (2009)
Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001
Authors: Peter D. Cole, Traci M. Blonquist, Veena Vijayanathan, Donna S. Neuberg, Lynda M. Vrooman, Stephen E. Sallan, Lewis B. Silverman, Yaron Finkelstein
Journal: Blood (2015)
Imaging mitochondrial dynamics in human skin reveals depth-dependent hypoxia and malignant potential for diagnosis
Authors: Dimitra Pouli, Mihaela Balu, Carlo A. Alonzo, Zhiyi Liu, Kyle P. Quinn, Francisca Rius-Diaz, Ronald M. Harris, Kristen M. Kelly, Bruce J. Tromberg, Irene Georgakoudi
Journal: Science Translational Medicine (2016)

In vivo, label-free evaluation of mitochondrial function in human skin epithelia noninvasively differentiates healthy from cancerous tissues.
Sleeping Beauty Transposon Insertional Mutagenesis Identifies Drivers of Erythroid Leukemia in Mice.
Authors: Keith R. Loeb, Bridget T Hughes, Brian M. Fissel, Yongiae E. Choi, Galina Pogosov, Sue E Knoblaugh, Brent L. Wood, Bruce E. Clurman
Journal: Blood (2012)
Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia
Authors: C Vesely, C Frech, C Eckert, G Cario, A Mecklenbräuker, U zur Stadt, K Nebral, F Kraler, S Fischer, A Attarbaschi, M Schuster, C Bock, H Cavé, A von Stackelberg, M Schrappe, M A Horstmann, G Mann, O A Haas, R Panzer-Grümayer
Journal: Leukemia (2016)

Children with P2RY8-CRLF2-positive acute lymphoblastic leukemia have an increased relapse risk. Their mutational and transcriptional landscape, as well as the respective patterns at relapse remain largely elusive. We, therefore, performed an integrated analysis of whole-exome and RNA sequencing in 41 major clone fusion-positive cases including 19 matched diagnosis/relapse pairs. We detected a variety of frequently subclonal and highly instable JAK/STAT but also RTK/Ras pathway-activating mutations in 76% of cases at diagnosis and virtually all relapses. Unlike P2RY8-CRLF2 that was lost in 32% of relapses, all other genomic alterations affecting lymphoid development (58%) and cell cycle (39%) remained stable. Only IKZF1 alterations predominated in relapsing cases (P=0.001) and increased from initially 36 to 58% in matched cases. IKZF1's critical role is further corroborated by its specific transcriptional signature comprising stem cell features with signs of impaired lymphoid differentiation, enhanced focal adhesion, activated hypoxia pathway, deregulated cell cycle and increased drug resistance. Our findings support the notion that P2RY8-CRLF2 is dispensable for relapse development and instead highlight the prominent rank of IKZF1 for relapse development by mediating self-renewal and homing to the bone marrow niche. Consequently, reverting aberrant IKAROS signaling or its disparate programs emerges as an attractive potential treatment option in these leukemias.
Liver Infiltration In Splenic Marginal Zone Lymphoma: Prevalence and Prognostic Implication
Authors: Eva Domingo-Domenech, Vicente Romagosa, Eva González-Barca, Marta Rodriguez-Aliberas, Ana Oliveira, Esmeralda de la Banda, Santiago Mercadal, Jose Sarra, Jose Petit, Alberto Fernandez de Sevilla
Journal: Blood (2010)
Activation of p53 Pathway In Erythroid Precursor Cells of Diamond-Blackfan Anemia Leads to Two Distinct Phenotypes
Authors: Hélène Moniz, Aurore Crétien, Corinne Hurtaud, Thierry Leblanc, Isabelle Marie, Gil Tchernia, William Vainchenker, Mohandas Narla, Lydie M. Da Costa
Journal: Blood (2010)
Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant
Authors: Gautam Borthakur, Amer Beitinjaneh, E. Lin, Jorge E. Cortes, Rajyalakshmi Luthra, Farhad Ravandi, Sherry A. Pierce, Akhshar Hemantkumar Patel, Gabriela Rondon, Sergio Giralt, Richard Champlin, Hagop Kantarjian, Marcos de Lima
Journal: Blood (2010)